SDC1 and plasma cell myeloma: Cell proliferation studies revealed that the addition of 1 μM lenalidomide and 10 nM bortezomib resulted in 60% decreased cell viability of CD138+ myeloma cells, and this decreased viability was not inhibited by eltrombopag or rhTPO (Figure 4A).